Nelson Van Denburg & Campbell Wealth Management Group LLC trimmed its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 63.6% during the first quarter, HoldingsChannel.com reports. The fund owned 1,000 shares of the specialty pharmaceutical company’s stock after selling 1,744 shares during the quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Jazz Pharmaceuticals were worth $142,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of JAZZ. Federated Investors Inc. PA lifted its stake in Jazz Pharmaceuticals by 191.3% in the 3rd quarter. Federated Investors Inc. PA now owns 32,626 shares of the specialty pharmaceutical company’s stock valued at $5,485,000 after buying an additional 21,426 shares in the last quarter. Vanguard Group Inc lifted its stake in Jazz Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc now owns 4,882,984 shares of the specialty pharmaceutical company’s stock valued at $820,975,000 after buying an additional 23,400 shares in the last quarter. Bank of Montreal Can lifted its stake in Jazz Pharmaceuticals by 6.1% in the 4th quarter. Bank of Montreal Can now owns 104,761 shares of the specialty pharmaceutical company’s stock valued at $12,986,000 after buying an additional 6,034 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Jazz Pharmaceuticals by 0.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,609 shares of the specialty pharmaceutical company’s stock valued at $11,852,000 after buying an additional 465 shares in the last quarter. Finally, Quantamental Technologies LLC purchased a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $186,000. Institutional investors own 94.73% of the company’s stock.
In related news, CFO Matthew P. Young sold 1,152 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $135.41, for a total value of $155,992.32. Following the completion of the sale, the chief financial officer now directly owns 38,700 shares of the company’s stock, valued at $5,240,367. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Paul Treacy sold 874 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $139.50, for a total transaction of $121,923.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,668 shares of company stock valued at $1,606,567. 3.90% of the stock is owned by corporate insiders.
A number of brokerages recently weighed in on JAZZ. HC Wainwright reaffirmed a “hold” rating and issued a $153.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, May 10th. ValuEngine raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 8th. Mizuho raised their price target on shares of Jazz Pharmaceuticals from $146.00 to $148.00 and gave the company a “neutral” rating in a research note on Wednesday, May 8th. BMO Capital Markets raised their price target on shares of Jazz Pharmaceuticals from $206.00 to $208.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. Finally, Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $182.41.
Jazz Pharmaceuticals stock opened at $136.76 on Friday. The firm has a market cap of $7.75 billion, a PE ratio of 11.17, a PEG ratio of 1.11 and a beta of 1.16. Jazz Pharmaceuticals PLC has a 12-month low of $113.52 and a 12-month high of $184.00. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.15 and a quick ratio of 3.01.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.44. Jazz Pharmaceuticals had a net margin of 24.88% and a return on equity of 27.35%. The firm had revenue of $508.19 million during the quarter, compared to analysts’ expectations of $466.55 million. During the same period in the previous year, the company earned $2.98 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 14.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 13.24 earnings per share for the current year.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: Compound Interest and Why It Matters When Investing
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.